Please use this identifier to cite or link to this item:
|Title:||Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.||Austin Authors:||Gleeson, Mary;Hawkes, Eliza A ;Peckitt, Clare;Wotherspoon, Andrew;Attygalle, Ayoma;Sharma, Bhupinder;Du, Yong;Ethell, Mark;Potter, Mike;Dearden, Claire;Horwich, Alan;Chau, Ian;Cunningham, David||Affiliation:||The Royal Marsden Hospital, London and Surrey, United Kingdom
Department of Oncology and Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia
Eastern Health, Melbourne, Australia
|Issue Date:||Aug-2017||metadata.dc.date:||2016-12-08||Publication information:||Leukemia & lymphoma 2017; 58(8): 1805-1813||Abstract:||Survival for transformed follicular lymphoma (tFL) has improved in the rituximab era and the need for upfront stem cell transplantation (SCT) is unclear. We evaluated the outcomes for all patients treated with first-line chemotherapy for histologically-proven tFL at our institution from 2003-2013 (n = 87). The majority of patients (89.7%) did not receive a SCT as part of first-line management. With a median follow-up of 7.8 years the 5-year overall survival (OS) for all patients was 61.7%. Patients treated with R-CHOP without upfront SCT (n = 55/87) had a 5-year OS of 64.3%. In a Cox regression analysis of the entire cohort (n = 87) International Prognostic Index (IPI) risk group and presence of B symptoms at transformation were independently associated with OS in multivariate analysis (MVA). Our analysis confirms the improved survival of tFL in the rituximab era even in the absence of upfront SCT consolidation.||URI:||http://ahro.austin.org.au/austinjspui/handle/1/17331||DOI:||10.1080/10428194.2016.1265114||PubMed URL:||27931133||Type:||Journal Article||Subjects:||Follicular lymphoma
|Appears in Collections:||Journal articles|
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.